Dana Investment Advisors’s Maravai LifeSciences MRVI Stock Holding History

Dana Investment Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,933	Closed	-$139K	–	436
2023 Q3	$139K	Hold	13,933	–	–	0.01%	402
2023 Q2	$173K	Buy	13,933 +885	+7%	+$11.9K	0.01%	386
2023 Q1	$183K	Hold	13,048	–	–	0.01%	391
2022 Q4	$187K	Buy	13,048 +3,882	+42%	+$61.1K	0.01%	394
2022 Q3	$234K	Hold	9,166	–	–	0.01%	376
2022 Q2	$260K	Buy	9,166 +2,112	+30%	+$66.9K	0.01%	382
2022 Q1	$249K	Hold	7,054	–	–	0.01%	322
2021 Q4	$296K	Buy	+7,054	New	+$286K	0.01%	297

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dana Investment Advisors's MRVI Position: Q4 2023 in Review

Dana Investment Advisors sold out of Maravai LifeSciences (MRVI) in Q4 2023, closing a stake of 13,933 shares — an estimated $139K sold.

Dana Investment Advisors first reported a position in MRVI in Q4 2021 and held it in 8 quarters. The position peaked at $296K in Q4 2021. 223 funds tracked by Wall St. Rank hold MRVI as of Q4 2023.

Dana Investment Advisors reported no remaining Maravai LifeSciences position as of Q4 2023 after selling out during the quarter.
Dana Investment Advisors sold 13,933 Maravai LifeSciences shares in Q4 2023, an estimated $139K.
Dana Investment Advisors first reported a position in Maravai LifeSciences in Q4 2021 and held it in 8 quarters.
Dana Investment Advisors's Maravai LifeSciences position peaked at $296K in Q4 2021.
223 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2023.

Based on Dana Investment Advisors's 13F filing for Q4 2023, filed 7 Feb 2024.